UnknownNot Applicable

Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients

Spain300 participantsStarted 2020-05-29

Plain-language summary

This is a prospective study analyzing the development of humoral immune response against SARS-Cov-2 in patients with previous Covid19: the aim is to compare the incidence, titration and evolution of IgG an IgM in a prospective cohort of liver transplant patients surviving to the first wave of Covid19, in comparison to not inmmunossupressed patients.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients recovered of covid 19 Informed Consent Exclusion Criteria: Chemotherapy on going Concomitant Autoimmune diseases

What they're measuring

Incidence of IgG against SARS-CoV-2

Timeframe: one year

Trial details

NCT IDNCT04410471

SponsorMagdalena Salcedo

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-05-29

Contact for this trial

Magdalena Salcedo, MD PhD

+34609751256 magdalena.salcedo@salud.madrid.org

View on ClinicalTrials.gov More Liver Transplant Infection trials